Table 3 |
|||||
|
Number of subjects categorized according to time spent in remission divided by subject-specific follow-up duration, for each of the remission criteria tested |
|||||
|
All subjects in BRASS with ≥2 years of follow-up |
|||||
|
|
|||||
|
Time in remission (%) |
DAS28-CRP < 2.6 N = 871a |
DAS28-CRP < 2.3 N = 871a |
SDAI N = 871a |
CDAI N = 871a |
ACR/EULAR N = 871a |
|
|
|||||
|
0 |
326 (37%) |
401 (46%) |
599 (69%) |
610 (70%) |
634 (73%) |
|
1-25 |
130 (15%) |
146 (17%) |
94 (11%) |
30 (3%) |
87 (10%) |
|
26-50 |
196 (23%) |
163 (19%) |
108 (12%) |
127 (15%) |
101 (12%) |
|
51-75 |
121 (14%) |
102 (12%) |
52 (6%) |
66 (8%) |
39 (4%) |
|
76-99 |
52 (6%) |
30 (3%) |
10 (1%) |
17 (2%) |
7 (1%) |
|
100 |
46 (5%) |
29 (3%) |
8 (1%) |
21 (2%) |
3 (0.3%) |
|
|
|||||
|
Overall mean time in remission |
31% |
24% |
12% |
15% |
10% |
|
|
|||||
|
Selected population of subjects in BRASS |
|||||
|
|
|||||
|
Time in remission (%) |
DAS28-CRP < 2.6 N = 309b |
DAS28-CRP < 2.3 N = 275b |
SDAI N = 168b |
CDAI N = 170b |
ACR/EULAR N = 158b |
|
|
|||||
|
1-25 |
77 (25%) |
89 (32%) |
58 (35%) |
54 (32%) |
60 (38%) |
|
26-50 |
133 (43%) |
111 (40%) |
62 (37%) |
72 (42%) |
64 (41%) |
|
51-75 |
49 (16%) |
37 (13%) |
30 (18%) |
24 (14%) |
18 (11%) |
|
76-99 |
28 (9%) |
21 (8%) |
6 (4%) |
7 (4%) |
8 (5%) |
|
100 |
22 (7%) |
17 (6%) |
12 (7%) |
13 (8%) |
8 (5%) |
|
|
|||||
|
Overall mean time in remission |
48% |
45% |
44% |
44% |
42% |
|
|
|||||
|
aSubjects in BRASS with ≥2 years of follow-up. Maximum number of visits is eight. bSubjects in BRASS with ≥2 years of follow-up, one or more visits in remission, according to the various definitions; ≥1 year follow-up after first visit in remission and not in remission at entrance into BRASS. Maximum number of visits is seven (because visit at entrance into BRASS is excluded). |
|||||
|
Prince et al. Arthritis Research & Therapy 2012 14:R68 doi:10.1186/ar3785 |
|||||
